Localized delivery of anti-fugetactic agent for treatment of cancer
AssigneeThe General Hospital Corporation
InventorMark C. Poznansky
Life of this patent
Estimating the term…
Abstract
The invention described herein relates to methods and compositions for treating cancer in a patient, or a tumor cell, by administering an effective amount of an antibody-anti-fugetactic agent complex.
Claims16
A kit of parts comprising:
- (a) a first container comprising an antibody-anti-fugetactic agent complex;
- wherein the complex consists of the antibody and the anti-fugetactic agent selected from the group consisting of AMD3100, KRH-1636, T-20, T-22, T-140, TE-14011, T-14012, TN14003, TAK-779, AK602, SCH-351125, NSC 651016, GF 109230X, tannic acid, and thalidomide, and wherein the antibody has specificity to a tumor antigen selected from the group consisting of EpCAM, CK20, CK30, CD33, CD47, CD52, CD133, CEA gpA33, mucins, TAG-72, CIXPSMA, folate binding protein, GD2 GD3, GM2, VEGH, VEGFR, integrin aV3, integrin a5, and ERBB2;
- and
- (b) a second container comprising an anti-cancer agent selected from the group consisting of a chemotherapeutic agent, an immunotherapeutic agent, and a radiotherapeutic agent.
A composition consisting of an anti-fugetactic agent complexed to an antibody, wherein the anti-fugetactic agent is selected from the group consisting of AMD3100, KRH-1636, T-20, T-22, T-140, TE-14011, T-14012, TN14003, TAK-779, AK602, SCH-351125, NSC 651016, GF 109230X, tannic acid, and thalidomide, and wherein the antibody is specific for a tumor antigen selected from the group consisting of EpCAM, CK20, CK30, CD33, CD47, CD52, CD133, CEA gpA33, mucins, TAG-72, CIXPSMA, folate binding protein, GD2 GD3, GM2, VEGH, VEGFR, integrin aV3, integrin a5, and ERBB2.
Dependencies are inferred from the claim text.